GSK puts a 'force ma­jeure’ on the man­u­fac­tur­ing of a pain med­i­cine in Pak­istan

As Pak­istan faces a se­ri­ous health cri­sis caused by ma­jor flood­ing, GSK is draw­ing back on the pro­duc­tion of a com­mon pain med­i­cine in the coun­try.

In a let­ter to Pak­istan’s stock ex­change, the phar­ma said that it has de­clared a “force ma­jeure” — a com­mon con­trac­tu­al clause that frees par­ties from li­a­bil­i­ties un­der ex­tra­or­di­nary cir­cum­stances — on the pro­duc­tion of the pain med­ica­tion Panadol in three forms, in­clud­ing tablets, ex­tra tablets and chil­dren’s Panadol liq­uid range.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER